Dec 26 |
Protalix BioTherapeutics Issues 2024 Letter to Stockholders
|
Nov 30 |
Levicept Appoints Eliot Forster as CEO
|
Nov 17 |
Protalix BioTherapeutics: Fiscal Challenges And Gout Therapy Prospects
|
Nov 7 |
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q3 2023 Earnings Call Transcript
|
Nov 7 |
PLX: More Regulatory Approvals
|
Nov 6 |
Protalix Biotherapeutics, Inc. (PLX) Q3 2023 Earnings Call Transcript
|
Nov 6 |
Protalix BioTherapeutics Inc (PLX) Reports Q3 2023 Financial Results
|
Nov 6 |
Protalix BioTherapeutics GAAP EPS of -$0.04 beats by $0.03, revenue of $10.35M beats by $2.71M
|
Nov 6 |
Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results
|
Nov 3 |
Protalix BioTherapeutics Q3 Earnings Preview
|